Antibody Therapeutics: J&J Acquires Firefly Bio for US$1bn

Firefly Bio specialises in Degrader Antibody Conjugates (DACs), which combine the unique strengths of Antibody Degrader Conjugates with selective protein degraders.

Johnson & Johnson (J&J) has announced that it has entered into a definitive agreement to acquire Firefly Bio for US$1bn.

Firefly Bio’s Firelink DAC platform for KRAS-driven tumours embraces J&J's oncology pipeline and ambition to develop targeted medicines for the most prevalent and hard-to-treat solid tumours.

Degrader Antibody Conjugate platform

Firefly Bio recently emerged from stealth with a US$94m Series A financing co-led by Versant Ventures, MPM BioImpact and Decheng Capital, with participation from Eli Lilly & Company, to advance a new class of cancer therapeutics known as degrader antibody conjugates (DACs). 

DACs combine the strengths of antibody-drug conjugates (ADCs) and targeted protein degraders, two powerful but individually limited therapeutic modalities. 

Traditional ADCs provide favourable pharmacokinetics and selective delivery to tumour cells but are often constrained by the toxicity of broadly cytotoxic payloads and their inability to directly eliminate intracellular disease-driving proteins. 

In contrast, protein degraders can selectively and catalytically remove intracellular targets but typically face challenges related to systemic exposure and cell-specific delivery. 

“KRAS has notoriously been considered an undruggable target and patients with KRAS-driven cancers continue to face limited treatment options with survival measured in months, not years,” says John Reed, M.D., Ph.D., Executive Vice President, Innovative Medicine, Research & Development, J&J. 

“We believe the proprietary Firelink platform will overcome the limitations of current treatments and diversify our pipeline with preclinical candidates for treating multiple types of solid tumours.”

Firefly’s platform integrates these complementary technologies by using potent catalytic protein degraders as ADC payloads, enabling precise targeting and degradation of intracellular proteins within cancer cells. 

Central to this approach is the company’s proprietary Firelink linker technology, which minimises free payload circulation and reduces uptake in healthy tissues, thereby improving the therapeutic index and lowering the doses required for efficacy. 

Preclinical studies in both solid and hematologic tumours have demonstrated substantial tumour volume reductions following a single low-dose administration, highlighting the potential of DACs to address previously undruggable intracellular targets while maintaining a favourable safety profile.

Oncology therapies

J&J has built one of the industry's most established oncology franchises, driven by a mission to eliminate cancer through scientific innovation and patient-centred care.

With more than three decades of experience in oncology, the company leverages its global research capabilities, clinical expertise and strategic partnerships to develop transformative therapies across both hematologic and solid tumour malignancies.

Its portfolio and pipeline span multiple myeloma, B-cell and myeloid malignancies, as well as prostate, bladder, lung, colorectal and head and neck cancers.

Beyond traditional drug development, J&J is advancing novel approaches such as interventional oncology, including intratumoural therapies delivered directly into tumours, while integrating data science and artificial intelligence across target discovery, drug design, patient stratification and clinical development.

Supported by specialised Centres of Excellence in biomarkers, companion diagnostics, biologics and precision medicine, the company is focused on accelerating the development of next-generation cancer treatments and improving outcomes for patients worldwide.

What is interventional oncology?

J&J’s Interventional Oncology (INTO) group represents a highly differentiated convergence of therapeutics, medical devices and data-driven oncology innovation aimed at redefining cancer treatment through intratumoural therapies.

By combining the company’s Innovative Medicine and MedTech capabilities, INTO is developing advanced treatment platforms that deliver therapeutics directly into tumours, enabling high local drug concentrations while minimising systemic exposure and associated toxicities.

The approach is particularly focused on lung cancer, head and neck cancers and other solid tumours where significant unmet clinical needs remain.

Beyond conventional cytotoxic therapies, INTO is exploring a broad range of next-generation modalities, including immunostimulatory agents, radio-enhancers, cell therapies, RNA-based therapeutics and controlled-release drug delivery systems designed to induce both local tumour destruction and systemic anti-tumour immune responses.

A key technological differentiator is the integration of precision delivery solutions, imaging, procedural guidance, biomarker development and AI-driven analytics to optimise treatment planning, administration, monitoring and outcome assessment.

Through collaborations spanning engineering, pharmaceutical sciences, interventional medicine and computational biology, INTO is building an ecosystem of localised therapeutic and delivery technologies that has the potential to overcome the limitations of systemic therapies and establish a new paradigm for precision oncology.